Repatha is a drug intended to treat patients with high cholesterol. The Pushotronex system offers a new, monthly single-dose administration option for the drug.
The device, created in conjunction with West Pharmaceutical Services in Exton, Pa., attaches to the body, allowing for hands-free administration.
The medicine may also be administered twice a week through the SureClick autoinjector.
Amgen, based in Thousand Oaks, Calif., expects the Pushtronex system to hit the market in early August.
More articles on supply chain:
Anti-HIV drug largely underused in San Francisco: 5 things to know
Drug monitoring programs show reduction in opioid overdoses: 6 things to know
FDA stops Juno’s cancer drug trials after 3 patients die
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.